Asthma treatment
Reading File
Finding Sources
Searching PubMed
"asthma"[MeSH Terms] AND "therapy"[MeSH Terms]
Searching the Web
asthma treatment guidelines 2025 GINA stepwise therapy
Finding Sources
Searching PubMed
"asthma" AND "inhaled corticosteroids"
Reading Web Page
https://www.sfhp.org/wp-content/files/providers/DUR/AMR_Prov…
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.
Asthma Treatment
Overview
Asthma is characterized by reversible airway obstruction from bronchial smooth muscle contraction, excessive secretions, and edema in response to triggers - most often infectious or allergic. Chronic airway inflammation is the central pathophysiologic driver, and this informs all pharmacotherapy decisions. Both NAEPP (U.S.) and GINA (global) guidelines use a stepwise approach: step up when uncontrolled, step down when control is sustained. Before escalating, always check inhaler technique and adherence first - poor technique or adherence accounts for uncontrolled asthma in up to 50% of referred patients.
- Harrison's Principles of Internal Medicine, 22nd Ed. (2025)
- Murray & Nadel's Textbook of Respiratory Medicine
- Washington Manual of Medical Therapeutics
- 2025 GINA Report
Key Paradigm Shift (GINA 2025)
SABA-only therapy is no longer recommended at any step. ICS-containing therapy is now required for all patients, including those with infrequent symptoms. The preferred reliever at all steps for adults/adolescents ≥12 years is as-needed low-dose ICS-formoterol (anti-inflammatory reliever, "AIR" approach), not a plain SABA.
Stepwise Pharmacotherapy (Adults & Adolescents ≥12 years)
| Step | Preferred Controller | Preferred Reliever | Notes |
|---|---|---|---|
| Step 1 | As-needed low-dose ICS-formoterol only | Same inhaler (AIR) | Intermittent symptoms; no daily maintenance needed |
| Step 2 | Low-dose ICS daily, OR as-needed ICS-formoterol | As-needed ICS-formoterol | LTRA is an alternative if minimal ICS side-effects are a concern (note: montelukast carries suicidal ideation warning) |
| Step 3 | Low-dose ICS-LABA (maintenance) | As-needed ICS-formoterol (SMART) | SMART = single inhaler for both maintenance and rescue |
| Step 4 | Medium-dose ICS-LABA (SMART) | Same inhaler | Add-on LTRA or LAMA (tiotropium) considered |
| Step 5 | High-dose ICS-LABA + phenotype-guided add-on therapy | As-needed | Refer for biologic therapy; consider add-on LAMA, LTRA, or low-dose oral corticosteroids |
SMART (Single Maintenance and Reliever Therapy) uses one ICS-formoterol inhaler for both scheduled maintenance and as-needed relief. It reduces severe exacerbations, emergency visits, hospitalizations, and total corticosteroid exposure.
Track 2 (alternative): A SABA reliever is retained, but low-dose maintenance ICS must also be prescribed - adherence to daily ICS must be confirmed before choosing this route.
ICS Dosing Reference (Selected Agents)
| Drug | Low Dose (≥12 yr) | Medium Dose | High Dose |
|---|---|---|---|
| Beclomethasone (QVAR) | 80-240 mcg/day | 240-480 mcg/day | >480 mcg/day |
| Budesonide (Pulmicort) | 180-600 mcg/day | 600-1200 mcg/day | >1200 mcg/day |
| Fluticasone propionate (Flovent) | 88-264 mcg/day | 264-440 mcg/day | >440 mcg/day |
| Ciclesonide (Alvesco) | 80-160 mcg/day | >160-320 mcg/day | >320 mcg/day |
ICS oral bioavailability varies widely: beclomethasone ~20%, fluticasone ~1%, mometasone <1%, ciclesonide activated only in lung tissue. Lower oral bioavailability reduces systemic effects (growth suppression in children, bone density loss, cataracts).
Drug Classes Summary
1. Inhaled Corticosteroids (ICS)
The cornerstone of maintenance therapy. Reduce airway inflammation, prevent exacerbations. Examples: budesonide, fluticasone, beclomethasone, mometasone, ciclesonide.
2. Short-Acting Beta-2 Agonists (SABA)
Salbutamol/albuterol, levalbuterol. Rapid bronchodilation for rescue. No longer used alone. If used, must be co-administered with ICS.
3. Long-Acting Beta-2 Agonists (LABA)
Formoterol (rapid onset - can be used as reliever), salmeterol (not suitable for rescue). Never use LABA as monotherapy in asthma - always in combination with ICS.
4. ICS-LABA Combinations
Budesonide/formoterol (Symbicort), fluticasone/salmeterol (Advair/Seretide), fluticasone furoate/vilanterol (Breo). Cornerstone of steps 3-5.
5. Leukotriene Receptor Antagonists (LTRA)
Montelukast, zafirlukast. Alternative or add-on. Montelukast carries an FDA black-box warning for neuropsychiatric events including suicidal ideation - weigh risks carefully.
6. Long-Acting Muscarinic Antagonists (LAMA)
Tiotropium (Spiriva Respimat). Add-on at steps 4-5. Can substitute for LABA at step 5 in select patients.
7. Biologics (Step 5, severe uncontrolled asthma)
| Biologic | Target | Indication | Dosing |
|---|---|---|---|
| Omalizumab | IgE | Moderate-severe allergic asthma; IgE 30-700 IU/mL; perennial allergen sensitivity | 150-375 mg SC q2-4 wk |
| Mepolizumab | IL-5 ligand | Severe eosinophilic asthma (AEC ≥150-300); GINA step 4-5 failures | 100 mg SC q4 wk |
| Reslizumab | IL-5 ligand | Severe eosinophilic asthma (AEC ≥400); ≥18 yr | 3 mg/kg IV q4 wk |
| Benralizumab | IL-5Rα | Severe eosinophilic asthma (AEC ≥300); ≥12 yr | 30 mg SC q4 wk |
| Dupilumab | IL-4Rα (blocks IL-4 & IL-13) | Moderate-severe; elevated FeNO (≥20-25 ppb) even without eosinophilia; OCS-dependent | SC q2 wk; reduces exacerbations ≥50%, may improve FEV1 more than anti-IL-5s |
| Tezepelumab | TSLP (alarmin) | Broadest indication - works even without elevated eosinophils or FeNO | SC q4 wk; reduces exacerbations 50-70% |
Biologics reduce exacerbations dramatically in their target endotypes (Type 2 high inflammation). Tezepelumab has the broadest applicability. Their high cost currently restricts use to step 5+.
Non-Pharmacological Strategies
- Smoking cessation
- Identification and avoidance of allergens/triggers (occupational, domestic)
- Weight reduction (obesity worsens asthma)
- Physical activity and pulmonary rehabilitation
- Vaccination (influenza, pneumococcal)
- House dust mite (HDM) sublingual immunotherapy (SLIT): consider for sensitized patients with allergic rhinitis and FEV1 >70% predicted, not well-controlled despite stable therapy
- Inhaler technique education and adherence monitoring
Management of Acute Asthma Attacks
Mild-to-moderate:
- Beta-2 agonist (SABA or ICS-formoterol) up to every 1 hour
- Consider 4-5x increase in ICS dose
- If not controlled after a few hours -> urgent care referral
Urgent care/ED:
- Assess PEFR or FEV1
- Nebulized beta-2 agonist up to every 20 min
- Supplemental oxygen to correct hypoxemia
- PEFR >60% predicted: likely responds to bronchodilators alone
- If PEFR <60% or failure to respond in 1-2 hours: IV/systemic corticosteroids
- Add nebulized ipratropium (anticholinergic) for additional bronchodilation
- Magnesium sulfate and LTRA are sometimes used adjunctively
Severe/Status asthmaticus:
- Continuous bronchodilator nebulization
- IV corticosteroids
- Noninvasive positive-pressure ventilation (NIPPV) to prevent intubation
- Heliox (helium-oxygen mixture) to reduce work of breathing
- Mechanical ventilation if needed: low respiratory rate, permissive hypercapnia strategy
- Important: Normal or rising PaCO2 in a distressed asthmatic signals impending respiratory failure
- Antibiotics only if infection is present
Special Populations
Pregnancy: Asthma affects ~4% of pregnant women; 1/3 will have exacerbations. Poorly controlled asthma poses greater risks (preterm labor, low birthweight, preeclampsia) than well-managed therapy. Most ICS medications are safe in pregnancy. Evaluate and manage as in non-pregnant adults with close monitoring of fetal well-being.
Children 5-11 years: GINA 2025 recommends ICS with SABA for relief at step 1 (using ICS with each SABA dose), SMART as an option at step 3 (preferred at step 4).
Children <5 years: Intermittent ICS for viral wheezing at step 2 (GINA 2025).
High-Risk Patients for Asthma Mortality
- Prior ICU admission or intubation for asthma
- Illicit drug use
- Poor perception of dyspnea
- Psychosocial problems or low socioeconomic status
- Overuse of SABAs
- Poor adherence to ICS
Recent Evidence (PubMed 2024-2025)
A 2025 network meta-analysis in JAMA (PMID 39465893) compared inhaled reliever therapies and provides updated evidence on ICS-formoterol vs SABA as rescue therapy. A 2025 systematic review in Annals of Allergy, Asthma & Immunology (PMID 40516649) examined triple therapy (ICS-LABA-LAMA) vs dual inhaler therapy for moderate-to-severe asthma - supporting the use of add-on LAMA at step 4-5.
Bottom line: Modern asthma management has moved decisively away from SABA monotherapy toward ICS-containing relief at every step, with SMART therapy as the preferred approach for steps 3-4, and phenotype-targeted biologics for step 5 severe disease. The goal at every step is the lowest effective treatment that maintains symptom control and minimizes future risk.
This is a shared conversation. Sign in to Orris to start your own chat.